Quattrin et al. [128] used a neutralizing antibody to TNFα (Golimumab) in a clinical trial in children and young adults with early-onset T1D, which resulted in improved endogenous insulin secretion, but all patients still required exogenous insulin. The gene discussed is INS; the disease is type 1 diabetes mellitus.